Latest Breaking News On - Gustave roussy cancer campus - Page 1 : comparemela.com

Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma

Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

France generalPierre fabreCaroline robertEncorafenib braftoviSun pharmaUniversity of parisPhio pharmaceuticalsBristol myers squibbCancer medicineGustave roussy cancer campus

Targeted induction before immunotherapy shows limited benefit in advanced melanoma

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed. However, findings presented at ASCO Annual Meeting suggest that individuals with elevated lactate dehydrogenase or liver metastases may benefit from the treatment regimen.

France generalUnited statesSunandana chandraCaroline robertByjosh friedmanMindy valcarcelSud universityBristol myers squibbGustave roussy cancer campusComprehensive cancer centerNorthwestern university

Blocking an allergy pathway unleashes antitumor immunity in mouse models of non-small cell lung cancer

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Thomas marronBarbarab maierBrians kimOakleyc olsonSamarth hegdeJill odonnell tormeyBriand brownFlorent ginhouxMark buckupKensuke miyakePauline hamonDeborahb doroshowRajwanth veluswamyMeriem belabedMiriam meradJessica le berichel

A type of allergy medicine might help treat l

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).  And in an early parallel study in humans, combining immunotherapy with dupilumab—an <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.00888/full" target=" blank">Interleukin-4</a> (IL-4) receptor-blocking antibody widely used for treating allergies and asthma—boosted patients' immune systems, with one out of the six experiencing significant tumor reduction.  The findings were described in the December 6 issue of Nature.

New yorkUnited statesColumbia universityNew providenceEast harlemNicole hallJill odonnell tormeyMiriam meradPauline hamonNicholas venturiniZhaoyuan liuFredr hirschJessica le berichelThomasu marronRajwanth veluswamyIgor figueiredo

ERC Synergy Grant for Immunotherapy of Liver Metastases

ERC Synergy Grant for Immunotherapy of Liver Metastases
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

France generalEric vivierFlorent ginhouxValeria fumagalliGeorg gasteigerMax planck societyJulius maximilian universitySynergy grants for groundbreaking researchEuropean research councilMax planck research groupMax planck research group for systems immunologyEuropean unionSystems immunologySynergy grantsDeveloped moleculesSan raffaele hospital